AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GT Biopharma shares surge 39.08% after-hours on progress in GTB-3650 trial and upcoming GTB-5550 IND submission.
ByAinvest
Friday, Nov 14, 2025 5:14 pm ET1min read
GT Biopharma (NASDAQ: GTBP) surged 39.08% in after-hours trading following the release of its third-quarter 2025 financial results and clinical updates. The stock’s sharp rise aligned with positive developments in its pipeline, including advancement of GTB-3650’s Phase 1 trial for hematologic malignancies to Cohort 4 at 10 µg/kg/day, with an update expected in Q1 2026. The company also announced plans to submit an IND application for GTB-5550, targeting B7H3-expressing solid tumors, by late December 2025 or January 2026. Management highlighted the safety profile of GTB-3650 and its potential competitive edge over other modalities, while reduced R&D expenses ($0.6 million vs. $1.3 million in Q3 2024) and a $2.6 million cash balance—sufficient to fund operations into Q1 2026—reinforced operational efficiency. These catalysts, emphasizing clinical progress and regulatory milestones, drove investor optimism in the after-hours session.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet